NEUP
Q3 2026 EPS Estimate
$-0.56
Sep 2, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus
Buy
2 analysts·Low coverage
63
Score
1 Buy (50%)1 Hold (50%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
150%
Hold
150%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$7.00
+87.4%
Consensus
$7.00
+87.4%
Bull
$7.00
+87.4%
12-Month Target Range2 analysts
$7.00$7.00$7.00
Current $3.74Consensus
Current Price
$3.74
Upside to Consensus
$3.26

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-39.67%
EPS
FY2028
Rev+900.44%
EPS
FY2029
Rev+0.50%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030E
Revenue Avg$6M$57M$57M$61M
Low$6M$57M$57M$61M
High$6M$57M$57M$61M
EBITDA Avg$-3M$-3M$-8M$-3M
Low$-3M$-3M$-8M$-3M
High$-3M$-3M$-8M$-3M
EBIT Avg$-4M$-4M$-8M$-3M
Low$-4M$-4M$-8M$-3M
High$-4M$-4M$-8M$-3M
Net Income Avg$-4M$-4M$-8M$-3M
Low$-4M$-4M$-8M$-3M
High$-4M$-4M$-8M$-3M
EPS Avg$-2.43$-2.46$-5.05$-2.14
Low$-2.43$-2.46$-5.05$-2.14
High$-2.43$-2.46$-5.05$-2.14
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-9M$-9M$-6M$-6M
Low$-9M$-9M$-6M$-6M
High$-9M$-9M$-6M$-6M
EPS Avg$-1.58$-1.64$-1.14$-1.18
Low$-1.58$-1.64$-1.14$-1.18
High$-1.58$-1.64$-1.14$-1.18
Analysts (Rev / EPS) / 1 / 1 / 1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 5, 2025H.C. Wainwright
Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
Target:$7.00
+63.9%from $4.27
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.